Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
Mastronardi
L
L
Puzzilli
F
F
Guiducci
A
A
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D001254:Astrocytoma / Q000737:chemistry / Q000401:mortality* / Q000532:radiotherapy; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D004305:Dose-Response Relationship, Drug; D005910:Glioma / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D016019:Survival Analysis; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D013629:Tamoxifen